Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D'Orazi, G.
Right arrow Articles by Patrignani, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Orazi, G.
Right arrow Articles by Patrignani, P.
Clinical Cancer Research Vol. 12, 735-741, February 2006
© 2006 American Association for Cancer Research

Human Cancer Biology

Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2–Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells

Gabriella D'Orazi1,3, Maria Gina Sciulli2, Valeria Di Stefano3, Sabrina Riccioni3, Milo Frattini4, Rita Falcioni3, Lucio Bertario4, Ada Sacchi3 and Paola Patrignani2

Authors' Affiliations: Departments of 1 Oncology and Neurosciences and 2 Medicine, Centre of Excellence on Aging, University "G. d'Annunzio" and Center for the Study on Aging, "Gabriele D'Annunzio" University Foundation, Chieti; 3 Department of Experimental Oncology, Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute, Rome; and 4 National Institute for Cure and Study of Tumours, Milan, Italy

Requests for reprints: Gabriella D'Orazi, Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy. Phone: 39-6-5266-2563; Fax: 39-6-5266-2505; E-mail: dorazi{at}ifo.it.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Homeodomain-interacting protein kinase-2 (HIPK2), a corepressor for homeodomain transcription factors, is a multifunctional kinase whose role in tumor cell survival is not completely clarified. We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers.

Experimental Design: In the human colorectal cancer cell line, RKO, we studied the effect of RNA interference for HIPK2 (HIPK2i) on prostanoid biosynthesis, both in the absence and in the presence of the cPLA2 inhibitor arachidonyl trifluoromethyl ketone. We evaluated the role of HIPK2 in the cPLA2 gene regulation by reverse transcriptase-PCR, transcriptional activity, and chromatin immunoprecipitation analyses. The involvement of HIPK2 in tumorigenicity in vivo was studied by tumor growth of HIPK2i cells in nude mice. We compared the gene expression of HIPK2 and cPLA2 in human colorectal cancer specimens by reverse transcriptase-PCR.

Results: HIPK2 silencing was associated with rousing PGE2 biosynthesis that was profoundly suppressed by the cPLA2 inhibitor. HIPK2 overexpression, along with histone deacetylase-1, inhibited the cPLA2-luc promoter that is strongly acetylated in HIPK2i cells. The tumors derived from HIPK2i cells injected in nude mice showed noticeably increased growth compared with parental cells. HIPK2 mRNA levels were significantly higher in colorectal cancers of patients with familial adenomatous polyposis, which showed undetectable cPLA2 levels compared with sporadic colorectal cancer expressing cPLA2.

Conclusions: Our findings reveal the novel mechanism of HIPK2 to restrain progression of human colon tumorigenesis, at least in part, by turning off cPLA2-dependent PGE2 generation.

Homeodomain-interacting protein kinase-2 (HIPK2) belongs to a family of corepressors for homeodomain transcription factors but, unlike other transcriptional corepressors, it has protein kinase activity (1). Its role as transcriptional regulator, often in complex with histone deacetylases (HDAC), has been shown for several different transcription factors including Smad1/4 and Brn3a (2–4). Moreover, HIPK2 plays a role in regulating p53 oncosuppressor functions through different posttranslational modifications. Thus, HIPK2 phosphorylates p53 at Ser46 in response to severe DNA damage, inducing apoptosis (5, 6). On the other hand, HIPK2 mediates p53 acetylation in response to moderate genotoxic damage, selectively inducing growth arrest (7). The role played by HIPK2 during apoptosis is also becoming evident in a p53-independent way. Thus, HIPK2 phosphorylates the antiapoptotic transcriptional corepressor, CtBP, targeting it for proteasomal degradation (8, 9), activates the c-Jun NH2-terminal kinase signaling pathway participating in transforming growth factor-ß-induced c-Jun NH2-terminal kinase activation and apoptosis (10), and induces caspase-dependent apoptosis in sympathetic neurons (11). Finally, silencing of endogenous HIPK2 by RNA-interference has been shown to increase cell survival after genotoxic damage (12), suggesting an involvement in restraining tumor progression.

Several lines of evidence record that prostaglandin E2 (PGE2) plays a leading role in carcinogenesis (13, 14). This is coherent with the biological traits of PGE2, i.e., trigger of proliferation, angiogenesis, and invasiveness, and inhibitor of apoptosis (15–21). The generation of the prostanoids is carried out through three consecutive enzymatic steps: (a) the release of arachidonic acid from membrane phospholipids by phospholipases, mainly cytosolic phospholipase A2{alpha} (cPLA2); (b) the transformation of arachidonic acid to the unstable endoperoxide PGH2 by prostaglandin H synthase, popularly known as cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2); (c) its metabolization to PGE2 by several PGE synthases (PGES; ref. 22). The rate-limiting step in PGE2 generation is the availability of arachidonic acid for COX-isozymes, which is dictated by cPLA2 expression and activity. cPLA2 is part of a complex gene family which consists of eight secretory and three cytoplasmic phospholipases. cPLA2 is the Ca2+-sensitive form which is ubiquitously expressed in most tissues and preferentially hydrolyzes phospholipids in the sn-2 position where arachidonic acid is esterified. Cellular cPLA2 activities are tightly regulated by different factors, including Ca2+ and phosphorylation (23, 24). Calcium ions drive the membrane translocation of cPLA2, whereas its phosphorylation of Ser505 by mitogen-activated protein kinases enhances the cellular activities of cPLA2 under physiologic conditions by elongating its membrane residence and thereby improving its overall affinity for the perinuclear membranes (25). Increasing evidence shows that cPLA2 expression could also be regulated at a transcriptional level (26, 27). Differently from the downstream enzymes, COX-2 and the microsomal PGES-1 (mPGES-1), which are widely expressed in precancerous and cancerous lesions of the intestine (28–31), cPLA2 overexpression is less frequently detectable in human colorectal cancer and often does not correlate with COX-2 expression (32, 33). This suggests that cPLA2 expression is tightly regulated during tumorigenesis; however, the mechanism involved is not yet known.

In the present study, we addressed (a) whether HIPK2 modulates PGE2 biosynthesis by constraining cPLA2 expression in human colon cancer cell line RKO using RNA-interference for HIPK2 function and (b) the consequence of HIPK2 depletion on tumor cell growth in vivo. Finally, we correlated the expression of HIPK2 and cPLA2 in human colorectal cancers. Our findings reveal the novel mechanism of HIPK2 to restrain progression of human colon tumorigenesis, at least in part, by turning off cPLA2-dependent PGE2 generation.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Cells and reagents. Human colon carcinoma cell line RKO-pSuper and HIPK2-interfered (HIPK2i) cell lines (12) and human lung cancer cell line H1299 were cultured in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Life Technologies) plus glutamine and antibiotics in a humidified atmosphere with 5% CO2 at 37°C.

cPLA2 selective inhibitor arachidonyl trifluoromethyl ketone (Cayman Chemical, Ann Arbor, MI; ref. 34) was dissolved in DMSO and stored at –20°C. [3H]-PGE2, [3H]-PGF2{alpha}, [3H]-6-keto-PGF1{alpha}, and [3H]-TXB2 were purchased from Perkin-Elmer Life Science Products (Brussels, Belgium).

Prostanoid analyses. RKO-pSuper and HIPK2i cells, grown to subconfluence in 60 mm Petri dishes, were cultured for 24 hours with 0.5% FBS before adding fresh medium with 10% FBS for the indicated time with or without the abovementioned inhibitor. Cell culture media were used to assess PGE2, PGF2{alpha} 6-keto-PGF1{alpha}, and TXB2 biosynthesis by specific RIA techniques, as previously described (35–37). PGD2 biosynthesis was measured in cell culture medium by using the PGD2-methoxylamina enzyme immunoassay kit (Cayman Chemical) following the manufacturer's instructions. Rabbit polyclonal anti-PGE2, anti-PGF2{alpha}, anti-6-keto-PGF1{alpha}, and anti-TXB2 antibodies were described elsewhere (36, 37).

Western blot analyses. Total cell extracts were prepared by incubating at 4°C for 30 minutes in lysis buffer [50 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCl, 5 mmol/L EDTA, 150 mmol/L KCl, 1 mmol/L DTT, 1% Nonidet P-40] plus a mix of protease inhibitors (Sigma Chemical Company, St. Louis, MO). Proteins were then separated by SDS-PAGE, blotted onto nitrocellulose (Bio-Rad, Richmond, CA) and immunoreacted with mouse monoclonal anti-cPLA2, anti-ß-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-phospho-cPLA2 (Ser505; Assay Designs Technology, Ann Arbor, MI; refs. 38, 39), antitubulin mouse monoclonal (Sigma BioSciences), and anti-HIPK2 rabbit antiserum (kindly provided by M.L. Schmitz, University of Bern, Switzerland). Immunoreactivity was detected with the enhanced chemiluminescence reaction kit (Amersham Corp., Arlington Heights, IL).

Cell transfection and luciferase assays. H1299 cells were transiently transfected by using the modified calcium phosphate precipitation method as described earlier (5). The amount of plasmid DNA was equalized in each sample by supplementing with empty vector. The expression vectors used in this study were: cPLA2-luc (kindly provided by R.A. Nemenoff, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO), Myc-HDAC1 (kindly provided by C.Y. Choi, Department of Biological Science, Sungkyunkwan University, Suwon, Republic of Korea), and HIPK2-Flag (5). Transfection efficiencies were normalized with the use of a cotransfected ß-galactosidase construct. Luciferase activity was assayed as previously described (5).

RNA extraction and reverse transcriptase-PCR analysis. RKO-pSuper and HIPK2i cells were grown to subconfluence in 100 mm dishes and collected. Total messenger RNA was extracted using the RNeasy mini kit (Qiagen S.P.A., Milan, Italy). Reverse-transcription reactions and PCR assays were done using the MuLV reverse transcriptase and the AmpliTaq DNA polymerase (Gene Amp RNA PCR kit, Perkin-Elmer, Roche Molecular System, Branchburg, NJ). The sequence of the primers used were as follows: human cPLA2 upstream, 5'-CTC TTG AAG TTT GCT CAT GCC CAG AC-3'; and downstream, 5'-GCA AAC ATC AGC TCT GAA ACG TCA GG-3'. Primers for human glyceraldehyde-3-phosphate dehydrogenase and HIPK2 have been described elsewhere (12). DNA products were run on 2% agarose gel and visualized by ethidium bromide using UV light.

Chromatin immunoprecipitation assay. Chromatin immunoprecipitation was done essentially as described (7). Protein complexes were cross-linked to DNA in living nuclei by adding formaldehyde (Carlo Erba, Milan, Italy) directly to the cell culture medium at 1% final concentration. Antibodies used were rabbit polyclonal anti-acetylated histone H4 (Cell Signaling) and no specific immunoglobulins (Santa Cruz) were as negative controls. In each experiment, the linearity of the signal was insured by amplification of increasing amounts of template DNA. Immunoprecipitation with no specific immunoglobulins (Santa Cruz) was done as a negative control.

In vivo tumorigenicity assay. Six-week-old female CD-1 nude (nu/nu) mice (Charles River Laboratories, Calco, Italy) were used for in vivo studies. They were housed in specific pathogen-free conditions and fed standard cow pellets and water ad libitum. Experiments were done in accordance with institutional standard guidelines for animal experiments. Each experimental group included eight animals. Solid tumors were obtained by injecting (i.m.) 3 x 106 viable RKO-pSuper and HIPK2i cells (three different interfered cell populations) suspended in 0.1 mL PBS into the right leg muscles. The mice were examined every day after injection. The tumors were detectable 10 days after the injection. Their dimensions were measured every other day and their volumes were calculated from caliper measurements of two orthogonal diameters (x and y, larger and smaller diameters, respectively) by using the formula: volume = xy2 / 2. Tumor growth was monitored for 1 month and the animals were sacrificed in accordance with institutional standard guidelines.

Analysis of HIPK2 and cPLA2 expression in human colorectal cancers. Tissue specimens from nine colorectal cancers were obtained with informed consent from previously untreated patients who underwent surgical resection at the National Institute for Cure and Study of Tumours (Milan, Italy). Immediately after tumor resection, an experienced pathologist selected and sampled the tumor specimen and its surrounding normal mucosa, which were subsequently stored at –80°C. The cohort of patients encompasses five consecutive sporadic colorectal cancers (mean age, 65 years; two with Duke's B, two with Duke's C, one with Duke's D) and four consecutive colorectal cancers (mean age, 47 years; two with Duke's A, two with Duke's C, and one with Duke's D) from patients with familial adenomatous polyposis (FAP; Apc germ line detected mutations) for which frozen material was available. Total RNA (1 µg), extracted from snap-frozen tumor tissue samples, stored at –80°C, was reverse-transcribed into cDNA using oligo (dT) primers and reverse-transcriptase (Superscript II, Life Technologies) according to the manufacturer's recommendations. The integrity of cDNA was detected by the amplification of the housekeeping ß-actin gene. cDNA (1 µL) was used as template for each reverse transcriptase-PCR (RT-PCR) reaction.

Statistical analysis. The data are expressed as mean ± SE. Statistical comparisons were made by ANOVA or t test followed by Student-Newman-Keuls test for in vitro and in vivo studies in experimental animals. In contrast, the Mann-Whitney U test was used for comparisons in human cancers.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
HIPK2 silencing induces prostanoid biosynthesis. We initially analyzed arachidonic acid metabolites released from RKO-pSuper and HIPK2i cells. We found that RKO-pSuper cells cultured in the presence of 10% FBS up to 24 hours did not release detectable levels of thromboxane (TXB2; a nonenzymatic metabolite of TXA2), PGF2{alpha}, PGD2, 6-keto-PGF1{alpha} (a nonenzymatic metabolite of prostacyclin), whereas only scanty levels of PGE2 and PGF2{alpha} (from <10 to 15 and 21 pg/106 cells, respectively) were detected. Conversely, depletion of HIPK2, confirmed by Western blot analysis (Fig. 1A, inset), was associated with the production of high levels of PGE2 and to a smaller extent of PGF2{alpha} (at 24 hours, PGE2 and PGF2{alpha} averaged 1,800 and 379 pg/106 cells, respectively), whereas the other prostanoids were undetectable (data not shown). These results suggest that HIPK2 silencing was associated with rousing prostanoid biosynthesis and that PGE2 was the major product of arachidonic acid metabolism. In Fig. 1A, the time-dependent production of PGE2 in RKO-pSuper cells and HIPK2i cells is shown. We next assessed the role of cPLA2 in mediating PGE2 biosynthesis. As shown in Fig. 1B, arachidonyl trifluoromethyl ketone, a potent and selective slow binding inhibitor of the cPLA2 (34), profoundly suppressed PGE2 biosynthesis demonstrating the dominant role of cPLA2 in prostanoid production in HIPK2-depleted cells and suggesting that HIPK2 might function as a repressor of cPLA2 in tumors.


Figure 1
View larger version (31K):
[in this window]
[in a new window]
  		Fig. 1. PGE2 production and cPLA2 expression in colon carcinoma cell line RKO-pSuper and HIPK2i cells. A, RKO-pSuper and HIPK2i cells grown to subconfluence in 60 mm Petri dishes were cultured for 24 hours with 0.5% FBS before adding fresh medium with 10% FBS. The culture medium was harvested at the indicated time and assayed for PGE2 biosynthesis by RIA. Columns, mean of four independent experiments done in duplicate; bars, ±SE. Inset, Western blot analyses of HIPK2 proteins levels in RKO-pSuper and HIPK2i cells. Anti-tubulin was used as protein loading control. B, HIPK2i cells grown as before with or without the cPLA2 selective inhibitor arachidonyl trifluoromethyl ketone at the indicated concentrations. The culture media were harvested at the indicated times and assayed for PGE2 biosynthesis. Columns, mean of three independent experiments done in duplicate; bars, ±SE. C, total cell extracts from RKO-pSuper and HIPK2i cells grown as in (A) were separated on a denaturing SDS-PAGE and analyzed by immunoblotting with the indicated antibodies. Anti-ß-actin was used as a protein loading control. D, densitometric analysis of the stained is reported (left, cPLA2/ß-actin ratio, and right, (p)cPLA2/ß-actin ratio). *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the corresponding time points of RKO-pSuper.

 
Immunoblot analysis of total cell extracts (Fig. 1C and D) showed that the scanty levels of prostanoids produced by RKO-pSuper cells were associated with low levels of cPLA2 protein, which was scarcely phosphorylated at Ser505. Conversely, enhanced PGE2 generation in HIPK2i cells was associated with a strong induction of cPLA2 protein, which is highly phosphorylated especially at 3 and 24 hours (Fig. 1C and D).

HIPK2 is involved in cPLA2 gene regulation. Previous reports have established a role for HIPK2 in transcriptional regulation acting as transcriptional corepressor (1–4). Here, we aimed to evaluate whether HIPK2 plays a role in the cPLA2 gene regulation. To this end, we first investigated the effect of HIPK2 overexpression on the transcriptional activity of the cPLA2-luc promoter. As HIPK2 functions as a transcriptional corepressor interacting, among others, with HDAC1 corepressor (2), we transfected H1299 cells with HDAC1 and HIPK2 expression vectors, along with the cPLA2-luciferase reporter vector. As shown in Fig. 2A, the efficient transcriptional activity of the cPLA2-luc promoter was reduced by HIPK2 overexpression and further inhibited by coexpressing HDAC1. Interestingly, HIPK2 overexpression did not affect transcriptional activity of COX-2 and mPGES1 promoters (data not shown). In agreement with the luciferase data, interference of the endogenous HIPK2 resulted in a strong increase of the acetylated histone H4 levels on cPLA2 promoter, as shown by chromatin immunoprecipitation analysis, compared with the pSuper control cells (Fig. 2B). These findings suggest a recruitment of the HDAC complex to the cPLA2 target promoter only when HIPK2 is expressed, allowing deacetylation of histone H4 that represses chromatin in vivo. To verify whether the results of transcription and chromatin immunoprecipitation analyses corresponded to an in vivo regulation of the cPLA2 gene, RT-PCR analyses were carried out using cDNAs derived from RKO-control and HIPK2i cells. As shown in Fig. 2C, cPLA2 gene was easily detected only in HIPK2i cells, suggesting that HIPK2 is required for cPLA2 transcriptional regulation. Altogether, these data support the notion that HIPK2 is a transcriptional corepressor that can suppress the cPLA2 gene in colon cancer cells likely through HDAC1 interaction.


Figure 2
View larger version (24K):
[in this window]
[in a new window]
  		Fig. 2. HIPK2-depletion increases cPLA2 expression derepressing its promoter. A, H1299 cells were transfected with the cPLA2-luc reporter, together with HIPK2 and HDAC1 expression vectors. Luciferase activity was then measured. Results, normalized to ß-gal activity, are representative of three independent experiments done in duplicate ±SE. B, lysates from RKO-pSuper and HIPK2i cells were subjected to chromatin immunoprecipitation using specific polyclonal anti-acet-H4 antibody. A sample representing linear amplification of the total input chromatin (Input) was included in the PCRs as a control. Additional controls included immunoprecipitation done with no specific immunoglobulins. C, RT-PCR analysis of RKO-pSuper and HIPK2i cells for the expression of the cPLA2 gene. glyceraldehyde-3-phosphate dehydrogenase is used as a loading control.

 
HIPK2 depletion increases in vivo tumor growth. To ascertain the involvement of HIPK2 in cell growth, proliferation and viability assays were first done. RKO-pSuper and HIPK2i cells were plated in the presence of 10% serum and cell number was determined at daily intervals. We found that both cell types grew in a similar extent, suggesting that HIPK2-depletion does not modulate the capability of the cells to grow in vitro (data not shown). Interestingly, we found that HIPK2i cells showed a longer capability to survive in in vitro growth culture conditions, compared with the pSuper control cells (data not shown). Morphologic observations of the cells show that HIPK2-depleted cells grow in clusters and easily detach from the plate compared with the pSuper control cells, suggesting the acquirement of anchorage-independent growth as a further index of transformation (Fig. 3A).


Figure 3
View larger version (40K):
[in this window]
[in a new window]
  		Fig. 3. HIPK2 depletion increases in vivo tumor growth. A, light photomicrographs of RKO-pSuper and HIPK2i cells cultured in vitro. Arrows, presence of cell clusters only in HIPK2i cells. B, RKO-pSuper and three different populations of HIPKi cells were injected in nude mice as described in Materials and Methods. The tumors were detectable 10 days after the injection. Then, they were measured every other day and tumor volumes calculated from caliper measurements. The tumor growth was monitored for 1 month. Points, mean of three independent experiments; bars, ±SE.

 
We next studied, for the first time, the involvement of HIPK2 in colon tumorigenicity in vivo. RKO-pSuper cells and -HIPK2i cells derived from three different interfered populations were injected i.m. in nude mice. The tumors were detectable 10 days after injection and the tumor sizes were determined every other day for ~20 days in addition. As shown in Fig. 3B, the tumors derived from HIPK2i cells showed noticeably increased growth compared with the pSuper control cells, with a median tumor mass 2.5 times bigger than in control cells. These data are in agreement with the potentiality of HIPK2i cells to survive in vitro and reinforces our hypothesis that loss of HIPK2 confers in RKO cells the capability to activate a survival pathway that is inhibited by HIPK2.

HIPK2 and cPLA2 gene expression in human colorectal cancers. To better address the physiologic relevance of the role played by HIPK2 in restraining tumor progression, we compared, for the first time, the gene expression of HIPK2 and cPLA2 in human colorectal cancer specimens collected from patients with FAP and sporadic colorectal cancer, using RT-PCR analysis. As shown in Fig. 4A and B, HIPK2 mRNA levels were different, in a statistically significant fashion, between the two groups of tumoral specimens, i.e., higher in colorectal cancers of patients with FAP than in those of sporadic colorectal cancer. Interestingly, we found that high expression of HIPK2 was associated with undetectable cPLA2 mRNA levels in the colorectal cancers of patients with FAP (Fig. 4A, left), whereas reduced expression of HIPK2 was associated with detectable levels of cPLA2 mRNA in sporadic colorectal cancers (Fig. 4A, right). These results might suggest that HIPK2 also restrains cPLA2 expression in vivo in humans. Interestingly, we found that HIPK2 expression in human colorectal cancers tended to correlate inversely with the staging of the tumors (Fig. 4C), suggesting that HIPK2 expression takes part in the control of tumor progression.


Figure 4
View larger version (36K):
[in this window]
[in a new window]
  		Fig. 4. mRNA expression in human colorectal cancers. A, HIPK2 and cPLA2 mRNA levels were detected by RT-PCR in colorectal cancers of patients with FAP and sporadic colorectal cancer. Glyceraldehyde-3-phosphate dehydrogenase was used as a control. B, densitometric analysis showing HIPK2/glyceraldehyde-3-phosphate dehydrogenase ratio in colorectal cancers of patients with FAP and sporadic colorectal cancer. C, Dukes' staging system showing that the expression of HIPK2 tended to correlate inversely with the staging of colorectal cancers.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In the present study, we showed evidence of a novel pathway by which HIPK2 protein kinase may curb tumor growth. HIPK2 silencing de-repressed cPLA2 gene transcription, thus unleashing the biosynthesis of PGE2. Observational and randomized controlled studies in many different population cohorts and settings have shown the protective effects of nonsteroidal anti-inflammatory drugs for colorectal cancers (40). Inhibition of PGE2 by nonsteroidal anti-inflammatory drugs has been proposed to be involved in these effects (41–45). In fact, PGE2 is the predominant prostanoid found in most colorectal cancers and is known to promote colon carcinoma growth by stimulating proliferation, angiogenesis, invasiveness, and by inhibiting apoptosis (3–9). A direct evidence of its involvement in colorectal tumorigenesis has been provided by studies of disruption of PGE2 receptor genes (46, 47). The rate-limiting step in PGE2 generation is the availability of arachidonic acid for COX-isozymes, which is dictated by cPLA2 expression and activity. cPLA2 can be induced by several cytokines and oncogenic Ras through transcriptional mechanisms (26). In fact, the cPLA2 promoter contains a number of putative regulatory elements including activator protein sites, nuclear factor {kappa}B sites, and glucocorticoid regulatory elements (48) that are critical for induction by oncogenic Ras (27). However, until now, no information is available on the possible regulation of cPLA2 expression by chromatin remodeling. Here, we show that HIPK2 could act as a corepressor for the cPLA2 promoter in agreement with the function of HIPK2 as transcriptional corepressor along with Groucho and HDAC (2). The role of HIPK2 as transcriptional regulator has been shown for several different transcription factors including homeodomain transcription factors, Smad1/4, and Brn3a (2–4).

The mechanism implicated in cPLA2-dependent intestinal tumorigenesis through the supply of arachidonic acid to COX-2—thus rousing PGE2 biosynthesis—is distinctly shown by the finding that deletion of cPLA2 suppresses APCMin-induced polyp number similarly to COX-2 deletion (49, 50). This finding shades the proposal that the level of free arachidonic acid and not PGE2 is the critical factor in tumorigenesis. Moreover, it suggests that cPLA2 is the predominant source of arachidonic acid for COX in the intestine. These results confirm our findings on a restrainable effect of HIPK2 on cPLA2 expression and provide incentives to perform further studies aimed to ascertain the molecular mechanisms involved in the regulation of PGE2 biosynthetic machinery by HIPK2 in more detail.

RKO-HIPK2i cells—releasing PGE2—were characterized by enhanced tumorigenicity in vivo versus parental cells when injected into nude mice. Our results obtained in experiments done in vitro and for the first time in vivo on tumor growth, suggest that HIPK2 depletion in tumor cells might likely activate a survival pathway that, in the presence of HIPK2, is negatively regulated. This is coherent with our results that HIPK2 gene expression tended to correlate inversely with the staging of colorectal cancers and with the expression of cPLA2 (Fig. 4B and C). Interestingly, high expression of HIPK2 was associated with undetectable cPLA2 mRNA levels in colorectal cancers of patients with FAP, whereas reduced expression of HIPK2 was associated with detectable levels of cPLA2 mRNA in sporadic colorectal cancers. Although a reduced expression of HIPK2 genes has been found in thyroid and breast cancers (51), further studies are required to clarify whether HIPK2 expression is a determinant of the type and/or the staging of neoplasia. Moreover, our results pave the way for investigating whether HIPK2 restrains tumorigenesis by turning off cPLA2-dependent PGE2 generation in different types of human neoplasias.

Our finding that cPLA2 is hardly detectable in patients with FAP might suggest that PGE2 generation has only a scanty contribution in tumorigenesis in this setting despite a wide expression of the downstream enzymes. This is nicely confirmed by the results of randomized clinical trials with selective COX-2 inhibitors in patients with FAP showing only a modest clinical efficacy (52, 53). Our observation is based on small numbers but should spur the performance of larger studies comparing clinical outcomes with molecular biomarkers (such as the concurrent expression of cPLA2, COX-2, and mPGES-1). The development of biomarkers to predict the efficacy of coxibs is this setting will enable us to implement a personalized therapy to restrict the drugs to patients likely to benefit from them, and to avoid the useless exposure of patients to the risk of cardiovascular hazards attached to coxibs (54).

In conclusion, our findings reveal the possible involvement of HIPK2 in restraining the progression of human colon tumorigenesis, at least in part, by turning off cPLA2-dependent PGE2 generation. This new property of HIPK2 is notable because cPLA2 expression dictates prostanoid biosynthesis despite the expression of the downstream enzymes (i.e., COX-2 and mPGES-1). Our observation of the tight control of cPLA2 expression in FAP may explain the modest efficacy of COX-2 inhibitors in polyp regression, shown in randomized clinical trials in this setting, despite the wide expression of COX-2 detected in the lesions (52, 53).


   Acknowledgments
 
We thank all the people cited in the text for their generous gifts. We also thank M.P. Visconti for technical support.


   Footnotes
 
Grant support: Associazione Italiana Ricerca sul Cancro (G. D'Orazi, P. Patrignani, and R. Falcioni); EU project EICOSANOX (P. Patrignani); MIUR COFIN (G. D'Orazi); Ministero della Salute (R. Falcioni).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/19/05; revised 10/10/05; accepted 11/10/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kim YH, Choi CY, Lee S, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 1998;273:875–9.
  2. Choi CY, Kim YH, Kwon HJ, Kim Y. The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription. J Biol Chem 1999;274:33194–7.[Abstract/Free Full Text]
  3. Harada J, Kokura K, Kanei-Ishii C, et al. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for Ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation. J Biol Chem 2003;3:38998–05.
  4. Wiggins AK, Wei G, Doxakis E, et al. Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuronal survival. J Cell Biol 2004;167:257–67.[Abstract/Free Full Text]
  5. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat Cell Biol 2002;4:11–9.[CrossRef][Medline]
  6. Hofmann TG, Moller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002;4:1–10.[CrossRef][Medline]
  7. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic DNA damage. Oncogene 2005;24:5431–42.[CrossRef][Medline]
  8. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 2003;115:177–86.[CrossRef][Medline]
  9. Zhang Q, Nottke A, Goodman RH. Homeodomain-interacting protein kinase-2 mediates CtBP phosphorylation and degradation in UV-triggered apoptosis. Proc Natl Acad Sci U S A 2005;102:2802–7.[Abstract/Free Full Text]
  10. Hofmann TG, Stollberg N, Schmitz ML, Will H. HIPK2 regulates transforming growth factor-ß-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 2003;63:8271–7.[Abstract/Free Full Text]
  11. Doxakis E, Huang EJ, Davies AM. Homeodomain-interacting protein kinase-2 regulates apoptosis in developing sensory and sympathetic neurons. Curr Biol 2004;14:1761–5.[CrossRef][Medline]
  12. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Re 2004;293:311–20.[CrossRef][Medline]
  13. Prescott S-M, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochem Biophys Acta 2000;1470:M69–78.[Medline]
  14. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11–21.[CrossRef][Medline]
  15. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;35:675–8.[Abstract/Free Full Text]
  16. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998;95:681–6.[Abstract/Free Full Text]
  17. Chang YW, Jakobi R, McGinty A, Foschi M, Dunn MJ, Sorokin A. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 2000;20:8571–9.[Abstract/Free Full Text]
  18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–16.[CrossRef][Medline]
  19. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493–01.[CrossRef][Medline]
  20. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289–93.[CrossRef][Medline]
  21. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor. Cancer Cell 2004;6:285–95.[CrossRef][Medline]
  22. Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001;107:1347–51.[Medline]
  23. Balsinde J, Balboa MA, Insel PA, Dennis EA. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999;39:175–89.[CrossRef][Medline]
  24. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002;68–69:3–58.
  25. Leslie CC. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids 2004;70:373–6.[CrossRef][Medline]
  26. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997;272:14501–4.[Abstract/Free Full Text]
  27. Blaine SA, Wick M, Dessev C, Nemenoff RA. Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. J Biol Chem 2001;276:42737–43.[Abstract/Free Full Text]
  28. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–8.[Medline]
  29. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–73.[Abstract/Free Full Text]
  30. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971–6.[Abstract/Free Full Text]
  31. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003;278:19396–05.[Abstract/Free Full Text]
  32. Soydan AS, Tavares IA, Weech PK, Temblay NM, Bennett A. High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue. Eur J Cancer 1996;32A:1781–7.[CrossRef]
  33. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res 1998;18:3283–7.[Medline]
  34. Riendeau D, Guay J, Weech PK, et al. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 1994;269:15619–24.[Abstract/Free Full Text]
  35. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317–27.[CrossRef][Medline]
  36. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–72.[Medline]
  37. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705–12.[Abstract/Free Full Text]
  38. Lin LL, Lin AY, DeWitt DL. Interleukin-1{alpha} induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. J Biol Chem 1992;267:23451–4.[Abstract/Free Full Text]
  39. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;72:269–78.[CrossRef][Medline]
  40. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252–66.[Abstract/Free Full Text]
  41. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc {delta}716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–9.[CrossRef][Medline]
  42. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254–9.[Medline]
  43. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293–7.[Abstract/Free Full Text]
  44. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040–4.[Abstract/Free Full Text]
  45. Giardiello FM, Casero RA, Jr., Hamilton SR, et al. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;126:425–31.[CrossRef][Medline]
  46. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093–6.[Abstract/Free Full Text]
  47. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28–32.[Abstract/Free Full Text]
  48. Wu T, Ikezono T, Angus CW, Shelhamer JH. Characterization of the promoter for the human 85 kDa cytosolic phospholipase A2 gene. Nucleic Acids Res 1994;22:5093–8.[Abstract/Free Full Text]
  49. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 2001;98:3935–9.[Abstract/Free Full Text]
  50. Takaku K, Sonoshita M, Sasaki N, et al. Suppression of intestinal polyposis in Apc({delta} 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem 2000;275:34013–6.[Abstract/Free Full Text]
  51. Pierantoni GM, Bulfone A, Pentimalli F, et al. The homeodomain-interacting protein 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun 2002;290:942–7.[CrossRef][Medline]
  52. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52.[Abstract/Free Full Text]
  53. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756–60.[Abstract/Free Full Text]
  54. Wong D, Wang M, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005;5:204–10.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. Puca, L. Nardinocchi, H. Gal, G. Rechavi, N. Amariglio, E. Domany, D. A. Notterman, M. Scarsella, C. Leonetti, A. Sacchi, et al.
Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown
Cancer Res., May 15, 2008; 68(10): 3707 - 3714.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D'Orazi, G.
Right arrow Articles by Patrignani, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Orazi, G.
Right arrow Articles by Patrignani, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation